Wedbush started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX - Free Report) in a report released on Friday morning, Marketbeat reports. The brokerage issued an outperform rating and a $18.00 price objective on the stock.
Other research analysts have also recently issued research reports about the company. BTIG Research assumed coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $40.00 target price for the company. HC Wainwright assumed coverage on Avalo Therapeutics in a research report on Thursday, October 24th. They set a "neutral" rating for the company.
Get Our Latest Report on Avalo Therapeutics
Avalo Therapeutics Trading Down 10.7 %
Shares of NASDAQ:AVTX traded down $0.87 on Friday, hitting $7.23. The company had a trading volume of 52,023 shares, compared to its average volume of 63,809. Avalo Therapeutics has a 1 year low of $4.24 and a 1 year high of $34.46. The firm's 50-day simple moving average is $7.78 and its two-hundred day simple moving average is $9.35.
Institutional Investors Weigh In On Avalo Therapeutics
A number of institutional investors have recently modified their holdings of AVTX. Ikarian Capital LLC increased its stake in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock valued at $9,218,000 after purchasing an additional 915,629 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Avalo Therapeutics in the third quarter worth $9,186,000. Geode Capital Management LLC boosted its position in shares of Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company's stock valued at $779,000 after buying an additional 94,742 shares during the last quarter. Bank of Montreal Can purchased a new position in Avalo Therapeutics in the 4th quarter worth about $446,000. Finally, Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics in the fourth quarter worth approximately $145,000. 87.06% of the stock is owned by hedge funds and other institutional investors.
Avalo Therapeutics Company Profile
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Further Reading
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
